DK1638551T3 - Immunosuppressive forbindelser og sammensætninger - Google Patents

Immunosuppressive forbindelser og sammensætninger

Info

Publication number
DK1638551T3
DK1638551T3 DK04752678.5T DK04752678T DK1638551T3 DK 1638551 T3 DK1638551 T3 DK 1638551T3 DK 04752678 T DK04752678 T DK 04752678T DK 1638551 T3 DK1638551 T3 DK 1638551T3
Authority
DK
Denmark
Prior art keywords
compositions
immunosuppressive compounds
diseases
immunosuppressant
prevention
Prior art date
Application number
DK04752678.5T
Other languages
English (en)
Inventor
Thomas H Marsilje
Nathanael S Gray
Tao Jiang
Wenshuo Lu
Shifeng Pan
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Application granted granted Critical
Publication of DK1638551T3 publication Critical patent/DK1638551T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK04752678.5T 2003-05-19 2004-05-19 Immunosuppressive forbindelser og sammensætninger DK1638551T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47193103P 2003-05-19 2003-05-19
PCT/US2004/015701 WO2004103309A2 (en) 2003-05-19 2004-05-19 Immunosuppressant compounds and compositions

Publications (1)

Publication Number Publication Date
DK1638551T3 true DK1638551T3 (da) 2012-04-02

Family

ID=33476902

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04752678.5T DK1638551T3 (da) 2003-05-19 2004-05-19 Immunosuppressive forbindelser og sammensætninger

Country Status (18)

Country Link
US (2) US7060697B2 (da)
EP (1) EP1638551B1 (da)
JP (1) JP4575920B2 (da)
CN (4) CN1787817B (da)
AT (1) ATE537825T1 (da)
AU (2) AU2004240649A1 (da)
BR (1) BRPI0410454A (da)
CA (1) CA2524054C (da)
CY (1) CY1112505T1 (da)
DK (1) DK1638551T3 (da)
ES (1) ES2379169T3 (da)
HK (1) HK1090559A1 (da)
MX (1) MXPA05012459A (da)
PL (1) PL1638551T3 (da)
PT (1) PT1638551E (da)
SI (1) SI1638551T1 (da)
WO (1) WO2004103309A2 (da)
ZA (1) ZA200508203B (da)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533587A1 (en) * 2002-07-30 2004-02-05 University Of Virginia Patent Foundation Compounds active in sphingosine 1-phosphate signaling
KR20110140139A (ko) * 2003-08-29 2011-12-30 오노 야꾸힝 고교 가부시키가이샤 Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
WO2005041899A2 (en) * 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
US7718704B2 (en) * 2004-02-24 2010-05-18 Irm Llc Immunosuppressant compounds and compositions
CN101884781B (zh) 2004-07-16 2012-07-18 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
KR101181090B1 (ko) 2004-10-12 2012-09-07 교린 세이야꾸 가부시키 가이샤 2-아미노-2-［2-［4-(3-벤질옥시페닐티오)-2-클로로페닐］에틸］-1,3-프로판디올 염산염 또는 그 수화물의 제조방법 및 그 제조 중간체
US7888527B2 (en) * 2004-12-06 2011-02-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
CA2591399C (en) * 2004-12-13 2014-05-20 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
EP1850865A2 (en) * 2005-02-08 2007-11-07 Novartis AG Antilymphocyte antibody induction by combination of an s1p receptor agonist/modulator and of immunosuppressive drugs
MX2007009848A (es) 2005-02-14 2008-03-10 Univ Virginia Agonistas de esfingosina 1-fosfato comprendiendo cicloalcanos y heterociclos de 5 miembros substituidos por grupos amino y fenilo.
NZ563522A (en) * 2005-04-22 2010-01-29 Daiichi Sankyo Co Ltd Heterocyclic compound with immunosuppressive activity
CN101291908A (zh) * 2005-08-23 2008-10-22 Irm责任有限公司 免疫抑制剂化合物和组合物
CA2624909C (en) * 2005-10-07 2013-10-01 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for treating liver disease containing 2-amino-1,3-propanediol derivative as active ingredient, and method for treating liver disease
AU2007209961A1 (en) * 2006-01-27 2007-08-09 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JP2009526073A (ja) * 2006-02-09 2009-07-16 ユニバーシティ オブ バージニア パテント ファンデーション 二環式スフィンゴシン−１−リン酸受容体アナログ
WO2008018427A1 (fr) * 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif
MX2009001457A (es) * 2006-08-08 2009-02-19 Kyorin Seiyaku Kk Derivados de aminoalcohol e inmunosupresores que contienen lo mismo como ingrediente activo.
WO2008064320A2 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
WO2008064337A2 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
CA2669102A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2209771A1 (en) * 2007-11-08 2010-07-28 Pfizer, Inc. Cyclobutyl carboxylic acid derivatives
GB0725101D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725104D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
WO2009131090A1 (ja) * 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
GB0807910D0 (en) * 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
EP2695615A3 (en) * 2008-07-23 2014-04-30 Novartis AG Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
SI2326621T1 (sl) 2008-07-23 2016-10-28 Arena Pharmaceuticals, Inc. Substituirani derivati 1,2,3,4-tetrahidrociklopenta(b)indol-3-il)ocetne kisline, uporabni pri zdravljenju avtoimunskih in vnetnih motenj
TWI392673B (zh) 2008-08-27 2013-04-11 Calcimedica Inc 調控細胞內鈣離子濃度之化合物
SI2342205T1 (sl) 2008-08-27 2016-09-30 Arena Pharmaceuticals, Inc. Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj
EP2344484B1 (en) * 2008-10-17 2016-06-08 Akaal Pharma Pty Ltd S1p receptors modulators and use thereof
EP2379498B1 (en) * 2008-12-18 2015-01-21 Novartis AG Polymorphic form of 1-(4-{1-[(e)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl) -azetidine-3-carboxylic acid
EP2376484B1 (en) * 2008-12-18 2015-04-22 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
JP2012512885A (ja) * 2008-12-18 2012-06-07 ノバルティス アーゲー 新規な塩
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
CA2780908A1 (en) * 2009-11-24 2011-06-03 Allergan, Inc. Novel compounds as receptor modulators with therapeutic utility
UY33177A (es) * 2010-01-13 2011-08-31 Sanofi Aventis Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido
TWI517851B (zh) * 2010-01-13 2016-01-21 賽諾菲阿凡提斯公司 含２，５，７－經取代唑并嘧啶環之雜環羧酸衍生物
WO2011086081A1 (de) * 2010-01-14 2011-07-21 Sanofi-Aventis 2,5-substituierte oxazolopyrimidinderivate
AR079884A1 (es) * 2010-01-14 2012-02-29 Sanofi Aventis Derivados de acido carboxilico heterociclicos que comprenden un anillo de oxazolopirimidina 2,5-sustituida
WO2011086079A1 (de) * 2010-01-14 2011-07-21 Sanofi-Aventis Carbonsäurederivate mit einem 2,5-substituierten oxazolopyrimidinring
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
SG10201501575VA (en) 2010-03-03 2015-04-29 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
CN103119038B (zh) 2010-04-23 2016-05-04 百时美施贵宝公司 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺
DK2563776T3 (da) 2010-04-27 2016-09-19 Calcimedica Inc Forbindelser, der modulerer intracellulært calcium
AU2011248579A1 (en) 2010-04-27 2012-11-29 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2592933B1 (en) 2010-07-16 2017-04-05 Anderson Gaweco Mif inhibitors and their uses
JP5916149B2 (ja) 2010-08-27 2016-05-11 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
JP2014505025A (ja) * 2010-12-03 2014-02-27 アラーガン インコーポレイテッド スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターとしての新規アゼチジン誘導体
BR112013013649A2 (pt) * 2010-12-03 2016-09-06 Allergan Inc derivados de oxima azetidina como moduladores de receptor de esfingosina 1-fosfato (s1p)
EA024967B1 (ru) 2010-12-07 2016-11-30 Амира Фармасьютикалс, Инк. Полициклический lpaантагонист и его применение
MX2013006040A (es) 2010-12-07 2013-08-26 Amira Pharmaceuticals Inc Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
DK2672823T3 (da) 2011-02-07 2016-11-28 Biogen Ma Inc S1p-modulerende midler
JP2014513077A (ja) 2011-04-05 2014-05-29 アミラ ファーマシューティカルス，インコーポレーテッド 線維症、疼痛、癌、ならびに呼吸器、アレルギー性、神経系または心血管疾患の治療に有用な３−または５−ビフェニル−４−イルイソキサゾールに基づく化合物
RU2013150173A (ru) * 2011-04-14 2015-05-20 Аллерган, Инк. Метиламинные производные бициклического фенила как модуляторы рецепторов сфингозин-1-фосфата
US8735402B2 (en) * 2011-07-07 2014-05-27 Sanofi Cycloalkyloxycarboxylic acid derivatives
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
MX2014004813A (es) * 2011-10-21 2014-05-20 Novartis Ag Regimen de dosificacion para un modulador o agonista del receptor s1p.
JP6209541B2 (ja) * 2012-02-03 2017-10-04 ノバルティス アーゲー Ｎ−（４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシ）−アセトイミド酸エチルエステルの製造方法
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR102053484B1 (ko) 2012-12-21 2019-12-06 국립연구개발법인 양자과학기술연구개발기구 뇌 안에 축적된 타우 단백질을 이미징하기 위한 신규한 화합물
WO2014127033A1 (en) * 2013-02-13 2014-08-21 Allergan, Inc. Azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
WO2014175287A1 (ja) 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
CN103408501B (zh) * 2013-08-14 2016-03-09 合肥医工医药有限公司 苄基嘧啶衍生物、其制备方法及其医药用途
EP3046905A4 (en) 2013-09-17 2017-03-22 Pharmakea Inc. Vinyl autotaxin inhibitor compounds
JP2016530210A (ja) 2013-09-17 2016-09-29 ファーマケア，インク． ヘテロ環式ビニルオートタキシン阻害剤化合物
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
AU2014352888B2 (en) 2013-11-22 2019-05-09 Sabre Therapeutics Llc Autotaxin inhibitor compounds
EP3102576B8 (en) 2014-02-03 2019-06-19 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN107405332A (zh) 2015-01-06 2017-11-28 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
EP3265456B1 (en) 2015-03-06 2020-11-18 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
EP4026549A1 (en) 2015-05-27 2022-07-13 Sabre Therapeutics LLC Autotaxin inhibitors and uses thereof
CA3002551A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
US10556907B2 (en) * 2015-08-28 2020-02-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic compounds as S1P modulators
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
AU2017278220C1 (en) * 2016-06-10 2022-10-13 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
EA201990621A1 (ru) 2016-09-07 2019-09-30 Фармакеа, Инк. Кристаллические формы ингибитора лизилоксидаза-подобного белка 2 и способы получения
KR102615565B1 (ko) 2016-09-07 2023-12-18 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
EP3582814B1 (en) 2017-02-16 2024-05-01 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
AU2018307919B2 (en) 2017-07-24 2022-12-01 Vitae Pharmaceuticals, Llc Inhibitors of RORϒ
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
SG11202010946YA (en) * 2018-05-09 2020-12-30 Aprinoia Therapeutics Inc Heteroaryl compounds and uses thereof
CN110776450B (zh) * 2018-07-27 2022-09-27 广东东阳光药业有限公司 一种辛波莫德晶型及其制备方法
EP3847158A1 (en) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
EP3892616A4 (en) * 2018-12-06 2022-07-27 Shanghai Jemincare Pharmaceuticals Co., Ltd. AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND MANUFACTURING METHOD AND APPLICATION OF AN AROMATIC RING DERIVATIVE
WO2020114477A1 (zh) * 2018-12-06 2020-06-11 上海济煜医药科技有限公司 作为免疫调节剂的化合物及其制备方法和应用
CN111484434A (zh) * 2019-01-29 2020-08-04 东莞市东阳光仿制药研发有限公司 一种辛波莫德晶型及其制备方法
CN113382982B (zh) * 2019-02-25 2023-01-31 广东东阳光药业有限公司 一种辛波莫德的制备方法
CA3161455A1 (en) 2019-11-13 2021-05-20 Aprinoia Therapeutics Limited Compounds for degrading tau protein aggregates and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH540247A (de) 1967-04-21 1973-09-28 Ciba Geigy Ag Verfahren zur Herstellung von heterocyclischen, Asthylendoppelbindungen enthaltenden Verbindungen
IL109161A0 (en) * 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
AU3325295A (en) * 1994-08-24 1996-03-14 Eli Lilly And Company Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists
US6110922A (en) * 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
US20040235794A1 (en) * 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
WO2003037271A2 (en) * 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
NZ533430A (en) * 2001-12-14 2005-12-23 Zentaris Gmbh Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR)
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
EP1470137B1 (en) * 2002-01-18 2009-09-02 Merck & Co., Inc. Edg receptor agonists
DE10207844A1 (de) * 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
BR0309562A (pt) * 2002-04-26 2005-02-15 Hoffmann La Roche Derivados de isoquinolina
JP2007186422A (ja) * 2004-01-28 2007-07-26 Astellas Pharma Inc アリールスルフィド誘導体

Also Published As

Publication number Publication date
CN1791395A (zh) 2006-06-21
US20050009786A1 (en) 2005-01-13
ZA200508203B (en) 2007-02-28
CN1787817B (zh) 2011-09-07
JP2006528987A (ja) 2006-12-28
CN1816544B (zh) 2011-06-08
US20050014724A1 (en) 2005-01-20
CN1791395B (zh) 2012-09-26
CA2524054A1 (en) 2004-12-02
CN1791592A (zh) 2006-06-21
US7060697B2 (en) 2006-06-13
WO2004103309A3 (en) 2005-03-03
HK1090559A1 (en) 2006-12-29
EP1638551A2 (en) 2006-03-29
CN1787817A (zh) 2006-06-14
CN1791592B (zh) 2012-07-04
SI1638551T1 (sl) 2012-04-30
CY1112505T1 (el) 2015-12-09
ATE537825T1 (de) 2012-01-15
JP4575920B2 (ja) 2010-11-04
AU2004240649A1 (en) 2004-12-02
PT1638551E (pt) 2012-03-28
EP1638551A4 (en) 2008-12-31
CN1816544A (zh) 2006-08-09
CA2524054C (en) 2012-04-24
WO2004103309A2 (en) 2004-12-02
AU2008203088A1 (en) 2008-08-07
PL1638551T3 (pl) 2012-05-31
US7462629B2 (en) 2008-12-09
EP1638551B1 (en) 2011-12-21
ES2379169T3 (es) 2012-04-23
BRPI0410454A (pt) 2006-06-13
MXPA05012459A (es) 2006-02-22

Similar Documents

Publication Publication Date Title
DK1638551T3 (da) Immunosuppressive forbindelser og sammensætninger
TNSN05294A1 (en) Immunosuppressant compounds and compositions
TW200505442A (en) Immunosuppressant compounds and compositions
WO2004113330A8 (en) Immunosuppressant compounds and compositions
WO2005082089A3 (en) Immunosuppressant compounds and compositions
WO2004071442A3 (en) Novel bicyclic compounds and compositions
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ATE433966T1 (de) Methylendipiperidinderivate
IL190654A (en) Methods of Methyl-Sulfonamido-Propanamido, Processes for Preparation and Medicines Containing Them
HK1089444A1 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
MA29088B1 (fr) Composes d'indazole-carboxamide.
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
EA200701978A1 (ru) Способ получения опиоидных модуляторов
MY153719A (en) Prokineticin 1 receptor antagonists
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
ATE524463T1 (de) 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung
FR2872165B1 (fr) Nouveaux derives de pyrimido-benzimidazole
ATE417042T1 (de) Substituierte 2,5-diaminomethyl-1h-pyrrole
UA84701C2 (ru) Замещенные индолы, способ их получения, их использования
ATE365556T1 (de) Verwendung von 3-aza-aoxa-dibenzo(e,h)azulenen zur herstellung von pharmazeutischen formulierung für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems